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ABSTRACT
Enzymes that modify the epigenetic status of cells
provide attractive targets for therapy in various
diseases. The therapeutic development of epigenetic
modulators, however, has been largely limited to
direct targeting of catalytic active site conserved
across multiple members of an enzyme family,
which complicates mechanistic studies and
drug development. Class IIa histone deacetylases
(HDACs) are a group of epigenetic enzymes that
depends on interaction with Myocyte Enhancer
Factor-2 (MEF2) for their recruitment to specific
genomic loci. Targeting this interaction presents an
alternativeapproachtoinhibitingthisclassofHDACs.
Wehaveusedstructuralandfunctionalapproachesto
identify and characterize a group of small molecules
thatindirectlytargetclassIIaHDACsbyblockingtheir
interactionwithMEF2onDNA.WeusedX-raycrystal-
lographyand
19FNMRtoshowthatthesecompounds
directly bind to MEF2. We have also shown that the
small molecules blocked the recruitment of class IIa
HDACs to MEF2-targeted genes to enhance the ex-
pression of those targets. These compounds can be
used as tools to study MEF2 and class IIa HDACs
in vivo and as leads for drug development.
INTRODUCTION
Alterations of epigenetic regulation are a characteristic of
many diseases. Small molecules that are being developed as
drugs against these diseases often function by modulating
the epigenetic control of cellular processes (1). This
approach ofdrugdesign isbest exempliﬁed bythediscovery
and development of small molecule inhibitors of histone
deacetylases (HDACs) that show anti-tumor activity as
well as therapeutic effects in neurodegenerative diseases
and inﬂammation (1). HDACs deacetylate histone and
non-histone proteins and are a major class of epigenetic
regulators of diverse cellular processes. This family of
enzymes can be phylogenetically divided into four classes:
class I (HDAC1, 2, 3 and 8), class II (HDAC4, 5, 7, 9, 6 and
10) and class IV (HDAC 11), while class III (sirtuins,
Sirt1-Sirt7) represents a structurally and functionally
distinct family of HDAC enzymes. Most of the currently
available HDAC inhibitors target the zinc-containing cata-
lytic domain common to class I, II and IV HDACs, while
some of these inhibitors appear to have limited isoform se-
lectivity (2). In general, the broad inhibition of HDACs
using active site inhibitors leads to complex cellular re-
sponses, which complicate mechanistic analyses and may
explain some of the undesired side effects of these drugs in
clinicalapplications(1).Therefore,itisimportanttodevelop
inhibitors that speciﬁcally target a particular member or
subset of HDACs to dissect the in vivo functions of
HDACs and to explore, and eventually exploit, the full
therapeutic potential of HDAC inhibition in a wide range
of diseases.
Class II HDACs can be further divided into class IIa
(HDAC4, 5, 7 and 9) and IIb (HDAC6 and 10). Class IIa
HDACs are highly expressed in muscle cells, neurons and
T cells. Extensive genetic studies have demonstrated the
important physiological roles of these HDACs in develop-
ment and adaptive responses of the muscle, nervous
and immune systems (3–8) where they participate in
calcium-dependent transcriptional responses (9,10).
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mechanisms of class IIa HDACs in those systems and
their potential as therapeutic targets (11). However,
recent studies reveal that class IIa HDACs do not
respond to most of the existing HDAC inhibitors (2). In
fact, compared with class I HDACs, class IIa HDACs
have a catalytic domain that is less active, leading to the
hypothesis that class IIa HDACs may function as
acetyllysine receptors (2). These observations emphasize
the need to develop speciﬁc inhibitors of this class for
mechanistic studies and therapeutic development. They
also raise the question of whether it is more effective to
develop subtype-speciﬁc inhibitors of class IIa HDACs by
focusing on functions other than the catalytic deacetylase
activity of the protein.
Class IIa HDACs contain a unique regulatory domain
N-terminaltothecatalyticdomain,whichisabsentinother
HDAC members. This regulatory domain mediates inter-
actions with a variety of other proteins, one of which is the
MADS-box family of transcription factor Myocyte
Enhancer Factor-2 (MEF2A-D). MEF2 plays a central
role in the development and adaptive response of diverse
tissues and organs (12); it is also selectively targeted for
mutations in several types of cancers (13–16). Class IIa
HDACs do not bind to DNA but depend on their inter-
action with the sequence-speciﬁc transcription factor
MEF2 for genomic targeting (17,18). This interaction is
mediated by a short amphipathic helix conserved in the
N-terminal regulatory domain of class IIa HDACs.
Crystallography analyses and in vitro biochemical studies
reveal that the amphipathic helix binds to a highly
conserved hydrophobic groove on the MADS-box/MEF2
domain of MEF2 (19–21). These studies suggest that small
molecules binding to the hydrophobic pocket of MEF2
could block the recruitment of class IIa HDACs to
DNA, thereby inhibiting the function of class IIa HDACs.
In this study, we used a structure-guided and
mechanism-based approach to identify and characterize
small molecule compounds that inhibit the MEF2:class
IIa HDAC interaction. Our results reveal that these
compounds can directly bind the MADS-box domain of
MEF2 and prevent the recruitment of class IIa HDACs to
the target genes and alter the expression of MEF2 target
genes. Therefore, our ﬁndings suggest that MEF2 is a
potential target for small molecule-based modulation of
epigenetic regulation of speciﬁc gene expression in
speciﬁc tissues.
MATERIALS AND METHODS
Drug treatment and luciferase assay
For the two-hybrid assay, cells were treated with 10mM
drug overnight unless indicated otherwise. The amount of
DMSO was kept below 0.2% V/V. A luciferase assay was
performed according to the manufacturer’s protocol
(Promega). The luciferase response was normalized
against the Renilla Luciferase as an internal control. The
data are presented as a mean±SD (n=2) of normalized
HDAC4:MEF2 luciferase response against the normalized
response values for GAL4-VP16 for each condition to
correct for non-speciﬁc inhibition of the luciferase signal.
Compound synthesis and preparation
BML-210 was purchased from Enzo Life Sciences.
NKL02, NKL08, NKL09, NKL11, NKL13, NKL22,
NKL30, NKL54 and NAP1407 were synthesized as
shown in Supplementary Figure S2. Stock solutions for
BML-210 (Enzo Life Sciences) and analogs were made
at 10mM concentration by dissolving in 100% DMSO
and stored at  20 C. TSA (Enzo Life Sciences) was
dissolved in DMSO as a 100mM stock solution and
stored at  20 C.
19F NMR
The experimental protocol is similar to that published
(22). The NMR samples were prepared in an aqueous
(pH 7.66) buffer containing 10mM HEPES, 250mM
NaCl and 1mM EDTA. Sample volumes were 700mL.
NKL54 solution was made by serial dilution of 10mM
NKL54 in 100% DMSO. NKL54 at 0.5–5mM was
incubated with MEF2A (1–95) at 0.5–10mM for 30min,
and the
19F NMR spectra were acquired on a Varian
VNMRS 500 Spectrometer at 25 C using a 54  pulse
with total acquisition and delay time of 1.6s for 3000
scans (80min acquisition time). An internal capillary con-
taining DMSO-d6 was used to obtain a lock signal.
A spectral width of 10ppm was used, and the data were
multiplied with an exponential function of 0.2Hz prior to
Fourier transformation. The CF3 resonance of the free
NKL54 was at  62.86ppm and that of the compound
bound to MEF2 was at  63.23ppm. The CF3 resonance
of the free compound without any added protein was also
observed at  62.86ppm. Chemical shifts are referenced to
triﬂuoroacetic acid. The ﬁnal DMSO concentration in the
samples was below 0.05%.
Crystallization and data collection
The DNA used in crystallization was the same as previ-
ously described (23) and puriﬁed as previously reported
(21). The MEF2A (1–78)/BML-210/DNA complex was
prepared in two steps. First, MEF2A (1–78) at 0.5mg/
ml was mixed with 10% volume of 10mM BML-210 in
DMSO and concentrated using a Biomax 5K cut-off ﬁlter
(Millipore) to a ﬁnal concentration of 17mg/ml. In the
second step, the MEF2A(1–78)/BML-210/DNA complex
was prepared by mixing the protein/BML-210 complex
and DNA at a 2:1 molar ratio. The amount of DMSO
was adjusted back to 10% volume to ensure drug solubil-
ity before setting crystal trays. Crystals were grown at
18 C by the hanging drop method with a reservoir
buffer of 24% PEG 4K, 50mM Tris HCl, pH8.18, 3.3%
glycerol, 142mM NaCl, 5mM MgCl2, 10mM CaCl2 and
0.004% NaN3. Plate-like crystals grew to 50–100mm over-
night. Crystals were stabilized in a harvest/cryoprotectant
buffer (30% PEG 4K, 50mM Tris HCl, pH 8.18, 1mM
BML-210, 18% glycerol, 142mM NaCl, 5mM MgCl2,
10mM CaCl2, 0.004% NaN3) and ﬂash frozen in liquid
nitrogen for storage and data collection. Data were col-
lected at a home X-ray source (copper anode on a Rigaku
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cooling system and Raxis IV+ +detector (MSC Inc.). The
structure of the MEF2A (1-78)/BML-210/DNA complex
was solved by molecular replacement using the
MEF2A (1–78)/DNA complex as a search model (23)
(see Supplementary Data for more details).
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) experiments were
performed according to standard procedures with the
following exceptions. Two 10cm dishes of transfected
HeLa cells were combined for each ChIP experiment
( 10 10
6 cells). Monoclonal anti-FLAG M2 antibody
(5mg) (Sigma) or normal rabbit IgG, sc-2027 (Santa
Cruz), as a control IgG was used for each ChIP.
Samples were sonicated in 0.5ml volume using a 550
sonic dismembrator (Fisher scientiﬁc) in 30s pulses, 90s
rest for 4min at a setting of 2. A 10ml sample was kept as
input. Puriﬁed samples were re-suspended in 62ml1 0m M
Tris HCl, pH 8, and puriﬁed input samples were then
diluted 1:4 before using 4ml of each sample as template
for real-time PCR. Samples were quantiﬁed using an
Opticon 2 real-time cycler (Bio Rad). Samples were
quantiﬁed in triplicate with primers speciﬁc for the FXN
promoter region (24), using the Ct method. The data
are presented as a mean fold change±SD of fold change
from two independent experiments. Statistical analysis for
mean fold change between different conditions was per-
formed using an independent T test (nDMSO=2,
nNKL30=2).
Image analysis
Imaging was done on a Bio-Rad MRC-1024 confocal
microscope with a  40 objective at  1 zoom as a sin-
gle optical section. Image analysis was performed using
ImageJ (NIH). Images used for quantiﬁcation did not
contain saturated pixels. Cells with a clearly deﬁned
nucleus, based on MEF2 staining, were chosen for
analysis. Background subtracted amounts of MEF2 and
HDAC4 within the nucleus was measured by mean ﬂuor-
escent intensity per pixel within the region marked
by nuclear MEF2. Data are presented as mean nuclear
HDAC4 intensity per pixel normalized against the
mean nuclear MEF2 intensity per pixel±SD. Statistical
analysis was performed using an independent
T test(nDMSO=25 nuclei, nNKL30=20 nuclei).
RESULTS
Structure-guided analysis of the HDAC4:MEF2
interaction
A potential challenge to inhibiting the binding of protein
complexes is the large protein–protein interfaces. Some of
these interfaces often require multiple mutations to
disrupt (25,26). Such interfaces are particularly difﬁcult
to inhibit using small molecules. To see if the class IIa
HDAC:MEF2 interface is sensitive to localized mutations,
we analyzed their binding interaction using structure-
guided mutations in a mammalian two-hybrid system.
Since the protein–protein interactions involved in the
recruitment of class IIa HDACs by MEF2 are highly
conserved (19), we used HDAC4 and MEF2D as repre-
sentative members of their respective families in our
studies. The structure of the HDAC4:MEF2 interface
(Figure 1A) was modeled after the crystal structure of
the closely related HDAC9:MEF2B complex (19). For
the mammalian two-hybrid assay (Supplementary
Figure S1a), MEF2D was fused with the GAL4 DNA
binding domain (GAL4-MEF2D) while the MEF2-
binding motif of HDAC4 (AA 155-220) was fused with
the viral transactivator VP-16 (HDAC4-VP16). This setup
allows us to detect the interaction between HDAC4 and
MEF2D with minimal interference from endogenous
factors. The HDAC4 fragment also lacks the catalytic
domain so that the deacetylase activity was excluded
from the assay. Human epithelial carcinoma cells (HeLa)
co-transfected with these constructs and the reporter
plasmid produced a strong signal comparable to that
generated by the positive control of GAL4-VP16
(Supplementary Figure S1b). Structure-guided mutation
of a number of residues at the HDAC4:MEF2D interface
(Figure 1A), including Leu67Ala and Leu67Asp of
MEF2D and Leu175Ala and Val179Ala of HDAC4,
had been shown to disrupt HDAC4:MEF2 interaction
in vitro (18,19). Each of these mutations also dimin-
ished the luciferase signal, demonstrating that the
HDAC4:MEF2 interface can be disrupted by site-speciﬁc
mutations in cells (Figure 1B). Expression levels of the
HDAC4 mutants was conﬁrmed by western blot
(Supplementary Figure S1c). Mutation of Val180Lys on
HDAC4, which weakened the binding of MEF2 by  60%
in vitro (Kd changed from 0.47 to 0.81mM) (19), partially
reduced the luciferase activity (Figure 1B). These results
suggest that the response from the mammalian two-hybrid
assay correlates very well with the molecular interaction
between HDAC4 and MEF2D. These ﬁndings also estab-
lish a sensitive and speciﬁc method for the detection of
HDAC4:MEF2 interaction inside cells.
Identiﬁcation of small molecule inhibitors of the
HDAC4:MEF2 interaction
To search for small molecules that bind MEF2 at the
HDAC-binding site, we performed virtual screening of
the ZINC database: a database of commercially available
compounds, using the crystal structure of the
HDAC9:MEF2 complex as a guide (27). Based on the
docking results, we tested a series of compounds using
the mammalian two-hybrid assay (Supplementary Figure
S1a). Most of the compounds were either cytotoxic or
showed no effect at 10mM concentration, while some
inhibited the HDAC4:MEF2 reporter as well as a
control reporter (Supplementary Figure S1d–S1f). The
most promising leads came from the pimeloylanilide
o-aminoanilide (PAOA) class (28) (Figure 1C). Our
subsequent analyses focused on one of the most
active members of this family, N-(2-aminophenyl)-
N0-phenyloctanediamide, which is commercially available
as BML-210. This compound inhibited the HDAC4-
VP16-driven reporter signal in a dose-dependent manner
5380 Nucleic Acids Research, 2012,Vol.40, No. 12with an apparent IC50 of  5mM (Figure 1D). BML-210
did not reduce the expression of HDAC4-VP16
(Supplementary Figure S1g) but did reduce a reporter
signal driven by GAL4-VP16 by 5.6 fold at 10mM
(Supplementary Figure S1h), indicating non-speciﬁc in-
hibition by this compound on the expression of luciferase
activity under our experimental conditions. However, the
same concentration of BML-210 decreased the reporter
signal driven by GAL4-MEF2D and HDAC4-VP16 by
about 26 fold (Supplementary Figure S1h), suggesting
that BML-210 has a speciﬁc disruptive effect on the
HDAC4:MEF2 interaction beyond its general inhibitory
effect. Similarly, analogs of BML-210 inhibited the
MEF2:HDAC4-VP16 reporter signal in transfected
monkey kidney cells (COS-7) (Figure 1E) and in mouse
embryonic ﬁbroblast cells (NIH 3T3) (Figure 1F). None of
the cell lines showed inhibitor-induced cell death under
our experimental conditions. In contrast, Trichostatin A
(TSA), a potent HDAC inhibitor that has been shown to
bind the catalytic site of HDAC (29), did not show
dose-dependent inhibition of the HDAC4-VP16-
mediated reporter signal (Figure 1G) in HeLa cells. TSA
reduced the HDAC4-VP16 luciferase response by only
1.4 fold at its IC50 value of 100nM while reducing
the GAL4-VP16 reporter signal by  2.7 fold
(Supplementary Figure S1i and S1j). These observations
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Figure 1. Identiﬁcation of small molecule inhibitors of the HDAC4:MEF2 interaction. (A) A structural model of the binding interface between
HDAC4 (gray) and MEF2 (red and yellow). (B) Analyzing the binding interaction between HDAC4 to MEF2 using structure-guided mutations in
the mammalian two-hybrid assay in HeLa cells. (C) Chemical structures of PAOA and BML-210. (D) Dosage-dependent inhibition of the reporter
signal driven by HDAC4:MEF2 interaction with BML-210 in HeLa cells. (E, F) Effect of BML-210 analogs on the HDAC4:MEF2-mediated
luciferase response in COS-7 cells (E) and NIH 3T3 cells (F). (G) Effect of TSA on the luciferase response driven by HDAC4:MEF2 in HeLa cells.
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the cause of the reduction of the luciferase response in the
two-hybrid assay. Taken together, our data suggest that
BML-210 and its analogs can inhibit HDAC4:MEF2
interaction inside cells.
Biochemical characterization of the BML-210:MEF2
interaction
To further analyze the binding interaction between
BML-210 and MEF2, we synthesized a number of
ﬂuorine-containing analogs of BML-210 for
19F NMR
analysis (Supplementary Figure S2a). One of these com-
pounds, termed NKL54 (Figure 2A), inhibited the
HDAC4:MEF2-driven luciferase signal (Figure 2B) and
showed a characteristic peak in the
19F NMR spectrum.
Incubation of NKL54 with MEF2A (1–95) produced a
new peak at the upper ﬁeld (Figure 2C), while increasing
the concentration of MEF2 resulted in a larger peak at the
upper ﬁeld and correspondingly a smaller peak at the
lower ﬁeld (Figure 2D). Based on titration analyses
using lower protein and ligand concentrations
(Supplementary Figure S2b), the Kd for the binding of
NKL54 to MEF2A (1–95) was estimated to be 0.5mM,
which is close to the equilibrium-binding constant of
HDAC4 to MEF2 (Kd 0.47mM) (19). We also
analyzed the effect of BML-210 on the binding of
HDAC4 to MEF2 in vitro using two different methods.
The ﬁrst was surface plasmon resonance (SPR) on a
Biacore instrument. Here, HDAC4 (AA 155–220) was
immobilized on a CM5 sensor chip, and puriﬁed
MEF2A (1–95) was used as the analyte. The binding of
MEF2A at various concentrations to the immobilized
HDAC4 generated a series of well-deﬁned sensograms
(Supplementary Figure S3a). Pre-incubation of MEF2
with increasing amounts of BML-210 decreased the
binding signals (Supplementary Figure S3b). In a second
approach, an HDAC4 fragment (AA 155–218) was
labeled by 5-Iodoacetamidoﬂuorescein (5-IAF) via
Cys194; the binding of MEF2A (1–95) to HDAC4 (155–
218) was monitored by ﬂuorescence anisotropy
(Supplementary Figure S4a). Incrementally increased
amounts of BML-210 caused a gradual decay of ﬂuores-
cence anisotropy, suggesting the displacement of HDAC4
from MEF2 by the small molecule (Supplementary Figure
S4b). Low solubility of BML-210 in aqueous solution in
both Biacore and ﬂuorescence anisotropy assays made
quantitative analysis difﬁcult (Supplementary Data).
Nevertheless, taken together, the in vitro binding data
strongly suggest that BML-210 and its analogs bind
MEF2 directly and competitively with HDAC4.
Structural analysis of the BML-210:MEF2:DNA complex
To analyze the structural details of the binding inter-
action, we co-crystallized BML-210 with MEF2A bound
to DNA. The crystals diffracted to 2.4A ˚ . The structure
was solved by molecular replacement using the
MEF2A:DNA complex as the search model (23)
(Supplementary Table S1). After initial rounds of rigid
body reﬁnement, electron density matching the shape of
BML-210 was clearly visible in the hydrophobic pocket of
MEF2 (Figure 3A). Since BML-210 has a nearly symmet-
ric structure (Figure 1C), its orientation in the complex
could not be uniquely assigned at the current resolution.
However, since the ring-shaped region at one end of the
electron density is surrounded by a number of hydropho-
bic residues including Leu66, Leu67, Thr70, Leu660,
Leu670 and Thr700 (the prime sign denotes residues from
the other monomer), we assigned this density to the phenyl
group (Figure 3B). At the other end, the ring-like electron
density is in a more hydrophilic environment surrounded
by Asn73, Gln560, Asp610 and Asp630. We assigned this
density to the 2-aminophenyl group, which makes van der
Waals contacts and potential hydrogen bonding inter-
actions with residues of MEF2 (Figure 3C). It is also
possible that BML-210 adopts two alternative orienta-
tions in the crystal and the observed electron density
represents a weighted average of the two populations.
The methylene groups of the octanediamide ﬁt snugly
between helix H2 of the two MEF2 monomers, making
numerous contacts to the main chain and side chain of
Figure 2. Detecting the binding of a ﬂuorinated analog of BML-210 to MEF2 by
19F NMR. (A) Structure of the ﬂuorinated analog NKL54.
(B) Similar to BML-210, NKL54 inhibits the HDAC4-VP16-driven reporter signal. (C)
19F NMR spectrum when the free ﬂuorinated compound is in
excess. (D)
19F NMR spectrum when the MEF2 protein is in excess.
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BML-210 adopts an extended conformation to bind the
surface groove of MEF2 (Figure 3D). Interestingly, a com-
parison with MEF2 complexes bound by Cabin1 and
HDAC9 shows that BML-210 shares some binding
features with natural ligands (19,20) (Figure 3E).
For example, the binding of the phenyl ring of BML-210
to the central hydrophobic pocket formed by Leu66,
Leu67 and Thr70 from each monomer is analogous to
that of Leu147 of HDAC9 (Figure 3E). Modeling
studies also suggest that some MEF2-binding proteins,
including members of the myocardin family, use an iden-
tical phenyl ring from phenylalanine to bind this pocket
(21,30).
The crystal structure can be used to guide the synthesis
of BML-210 derivatives to improve the afﬁnity and
pharmacological properties. For example, the binding of
BML-210 to the hydrophobic pocket of Leu66, Leu67,
Thr70, Leu660, Leu670 and Thr700 is largely dependent
on the phenyl group that does not completely ﬁll the
pocket, suggesting that substitutions on the phenyl ring
could be an attractive strategy for optimization. The
2-aminophenyl group of BML-210, however, engages in
numerous hydrogen-bond interactions with MEF2, which
imposes more constraints on synthetic modiﬁcations.
Another important factor is the methylene chain whose
length is limited by the groove on MEF2. The narrow
width of the groove also suggests that substitutions on
the methylene chain may be highly limited. Considering
these factors, we synthesized a series of new BML-210
analogs (Figure 4A, Supplementary Figure S2a). These
compounds were designed to systematically explore the
effect of ring substitutions and the length of the methylene
linker on inhibiting the MEF2:HDAC4 interaction in the
two-hybrid assay (Figure 4B, Supplementary Figure S2c).
As shown in Figure 4B, substitutions on the phenyl rings
and variations of the linker length indeed showed strong
effect on inhibition of the MEF2:HDAC4 interaction. For
example, compounds with a ﬁve-carbon linker were gen-
erally more active than those with a six-carbon linker.
Most notably, NKL11 that lacks the putative zinc
chelating 2-amino group also showed signiﬁcant inhibition
in the two-hybrid assay. By contrast, NAP1407, a close
analog of the benzamide HDAC inhibitor MS275, is com-
pletely inactive. These observations suggest that BML-210
and its derivitives act outside the catalytic site of HDAC
to inhibit the MEF2:HDAC4 interaction.
BML-210 blocks MEF2-dependent recruitment
of HDAC4 to DNA
BML-210 has been shown to enhance the expression of
frataxin in Friedreich’s ataxia (FRDA), a neurode-
generative disease associated with trinucleotide repeat
expansion that apparently leads to epigenetic silencing of
the FXN gene (24,31). Although the mechanism seems to
involve induced histone acetylation, more potent and
non-discriminatory HDAC inhibitors such as SAHA did
not activate the expression of frataxin, suggesting that
A
DE
BC
Figure 3. Structural characterization of the binding of BML-210 to MEF2A. (A) Electron density (blue mesh) matching the shape of BML-210 (blue
stick) was identiﬁed in the hydrophobic pocket of MEF2 (red and yellow ribbon). (B) The phenyl group of BML-210 is surrounded by a number of
hydrophobic residues of MEF2. (C) The 2-aminophenyl group of BML-210 interacts with a number of residues on MEF2. (D) A surface repre-
sentation showing that the methylene groups of the octanediamide ﬁt snugly between helix H2 of the two MEF2 monomers and that BML-210
adopts an extended conformation to bind the surface groove of MEF2. Positive and negative surface potentials are indicated by red and blue,
respectively. (E) Structural superposition using MEF2 as the reference showing that BML-210 and HDAC9 share the same binding site on MEF2
and that the synthetic compound mimics some of the binding interactions of the natural ligands.
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involved in frataxin expression (24).
To further explore the role of MEF2 in frataxin expres-
sion, we analyzed the promoter region of the FXN gene
for putative MEF2 binding sites. We found four highly
conserved A/T rich elements that resemble the consensus
MEF2-binding sequence (50-CTA(A/T)4TAG-30) approxi-
mately 200bp upstream of the transcription start site
(Supplementary Figure S5a). These putative MEF2 sites
are located in the MIR (mammalian-wide interspersed
repeats) region of the frataxin promoter that had been
previously reported to contribute signiﬁcantly to the
activity of the frataxin promoter (32). Recent studies
also show that SRF, another MADS-box transcription
factor that shares a similar DNA binding site with
MEF2, regulates the expression of Frataxin in human
cells (33). We detected the enrichment of MEF2 at the
FXN promoter in the FRDA cells using ChIP
(Supplementary Figure S5b). Therefore, to see if BML-
210 could mediate its effect on frataxin expression by dis-
rupting MEF2/co-repressor complexes, we analyzed the
binding of MEF2 and HDAC4 to the frataxin promoter
using ChIP in transfected cells. We showed that MEF2
could bind and recruit HDAC4 to the frataxin promoter
(Figure 5A). Treatment of the cells with BML-210 blocked
this recruitment, evident by diminished binding of
HDAC4 (Figure 5B), but had little effect on the occu-
pancy of the locus by MEF2 (Figure 5C). This effect is
not due to reduced expression of HDAC4 (Supplementary
Figure S5c), but consistent with BML-210-mediated inhib-
ition of HDAC4 binding to MEF2. The results presented
here suggest that BML-210 could block the binding of
HDAC4 to MEF2-targeted promoters in vivo.
BML-210 analogs alter the cellular localization of
HDAC4 in vivo
Previous studies have shown that direct binding to MEF2
is required for nuclear targeting of HDAC4 and mutation
of the key MEF2-binding residue Leu175 in HDAC4
resulted in a diffusive distribution of HDAC4 in the cyto-
plasm (18). To see if BML-210 and its analogs can mimic
this effect in vivo, we analyzed the cellular localization of
HDAC4 in COS-7 cells and FRDA lymphoid cells using
immunocytochemistry (Figure 6A, C). Since the com-
pounds NKL30 and NKL54 seem to be more soluble
than BML-210 and more potent in inhibiting the MEF2
and HDAC4 interaction in the luciferase assay (Figure
4B), these compounds were used for the immunocyto-
chemistry experiments. Cells were treated with 10mM
NKL30 overnight (ON) and immunostained with
antibodies against MEF2 and HDAC4. Drug treatment
did not result in signiﬁcant cytotoxicity under the assay
conditions. As shown in Figure 6A, NKL30 treatment
clearly induced a much more diffusive localization
pattern of HDAC4 (lower right panel) compared to the
vehicle (upper right panel). Since the amount of nuclear
MEF2 did not change signiﬁcantly (P>0.25) between
A
B
Figure 4. Development of BML-210 analogs. (A) Chemical structures of BML-210 analogs. (B) Effect of BML-210 analogs on the
HDAC4:MEF2-mediated luciferase response. Response is indicated as mean percentage from the DMSO luciferase response±SD (n=2).
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Figure S6a and S6b), MEF2 was used for staining the
nucleus and also for normalizing the nuclear HDAC4
level for quantitative analysis. The data indicated that
the NKL30-treated cells have 21% less HDAC4 in the
nucleus (P<0.001) (Figure 6B). We also detected the
effect of NKL54 on the cellular distribution of HDAC4
in the FRDA lymphoid cell line (GM15850) (Figure 6C).
NKL54 decreased the co-localization of MEF2 and
HDAC4 compared to the vehicle. There was no
apparent effect on the nuclear localization of MEF2.
Although we could not quantify the effect of NKL54 on
the cellular localization of HDAC4 in the FRDA cells due
to technical difﬁculties, this result, together with the
more diffusive distribution of HDAC4 in the COS-7
cells, suggests that BML-210 and its analogs can disrupt
MEF2:HDAC4 co-localization in vivo, presumably
through the inhibition of MEF2:HDAC4 interaction.
DISCUSSION
In this study, we have demonstrated that the interaction
between class IIa HDACs and MEF2 can be inhibited by
small molecules. We have identiﬁed a class of compounds
belonging to the PAOA family that bind MEF2 at the
same site as class IIa HDACs and inhibit their binding
interactions. We have also shown that these compounds
can block the recruitment of class IIa HDACs to MEF2
targeted promoters without affecting the occupancy of
MEF2 on DNA. Our ﬁndings suggest that the observed
effect of PAOA compounds on the level of histone acetyl-
ation and gene expression (24) may include an indirect
effect on the inhibition of MEF2 and class IIa HDAC
interaction.
BML-210 or PAOA-like compounds were originally
discovered as HDAC inhibitors that selectively induced
acetylation of histone but not tubulin (28,34), presumably
through the inhibition of HDACs other than HDAC6, a
tubulin-speciﬁc deacetylase (35,36). The molecular mech-
anisms by which these benzamide derivatives inhibit
HDAC function have remained unclear. The evidence of
direct binding to MEF2 presented here suggests a previ-
ously unknown mechanism for the action of these mol-
ecules that does not involve targeting the active site of
HDAC, but rather the protein–protein interactions
between HDAC and its functional partners. In fact,
these results provide the ﬁrst example of subtype-selective
inhibition of HDACs by targeting the protein complex
between class IIa HDACs and MEF2. We have shown
that these compounds, consistent with this model, can
disrupt the co-localization of a class IIa HDAC and
MEF2 in vivo.
Additionally, a number of our observations suggest that
the FXN gene, a previously unknown target of MEF2,
might be regulated by MEF2. Close examination of the
FXN promoter revealed a number of conserved MEF2
binding sites in an enhancer region previously shown to
be important for frataxin expression (32). ChIP analyses
have shown that MEF2 binds this region in vivo. In fact, in
transiently transfected cells, the class IIa HDAC member
HDAC4 was shown to bind this region and the binding
was enhanced in MEF2 co-transfected cells, suggesting a
MEF2 mediated recruitment. Although our efforts as well
as others to analyze the role of endogenous HDACs on
the frataxin promoter in FRDA cells were unsuccessful
(37), our data suggest that BML-210-like compounds
activate FXN expression in Friedreich’s ataxia through
MEF2-dependent mechanisms. It is possible that BML-
210 like compounds may activate the expression of the
FXN gene by blocking MEF2-mediated recruitment of
transcription co-repressors other than HDACs, such as
Cabin1 (20). This model provides a plausible explanation
for the intriguing observations that a number of com-
pounds, such as 7b, 10b, and 14b described by Hermann
AB C
Figure 5. BML-210 inhibits MEF2-dependent recruitment of HDAC4 to the frataxin promoter. ChIP assays were performed with chromatin from
HeLa cells transfected with FLAG-tagged HDAC4 and GFP and/or FLAG-tagged MEF2C. Drug-treated and control-treated chromatin were
immunoprecipitated with anti-FLAG antibody and normal rabbit IgG as negative control, and precipitated genomic DNA was ampliﬁed with
primers ﬂanking the MEF2 site on the endogenous FXN promoter. (A) Co-transfection of HeLa cells with both MEF2C and HDAC4 resulted in
enhanced enrichment of HDAC4 on the FXN promoter. (B) 6h treatment with 10mM BML-210 diminished the MEF2C-mediated enrichment of
HDAC4 on the Frataxin promoter (P<0.04). (C) The BML-210 treatment did not signiﬁcantly affect the MEF2C enrichment on the FXN
promoter. Lower panels are schematic interpretations of the ChIP data. FXNp: frataxin promoter (magenta line); MEF2 dimer (blue triangles);
HDAC4 (green bar); BML-210 (red triangle).
Nucleic Acids Research, 2012,Vol.40, No. 12 5385Figure 6. BML-210 analog NKL30 disrupts MEF2: HDAC4 co-localization in vivo.( A) Analysis of the cellular localization of MEF2 and HDAC4
in COS-7 cells treated with DMSO and NKL30 using immunocytochemistry, showing that NKL30 induced a delocalization of HDAC4 but showed
no apparent effect on the cellular distribution of MEF2. The arrows point at the nucleus of a DMSO treated COS-7 cell and an NKL30 treated
COS-7 cell. (B) Quantitative image analysis showing that NKL-30 reduced the amount of HDAC4 in the nucleus by 21% (P<0.001). (C)
Immunocytochemistry showing cellular localization of MEF2 (red) and HDAC4 (green) in FRDA lymphoid cell line (GM15850) treated with
DMSO and NKL54. NKL54 induced delocalization of HDAC4. There was no apparent effect on the cellular distribution of MEF2 in the
FRDA cells.
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lack the characteristic functional groups of HDAC inhibi-
tors (24). These compounds showed little or no inhibition
on HDAC activity yet enhanced the expression of the
FXN gene substantially (24). Characterizing the details
of the FXN induction mechanisms will require further
studies. The compounds developed here can be used for
dissecting the function of MEF2 and class IIa HDACs in
FXN regulation and other cellular processes.
Recent studies reveal that MEF2 is highly mutated in
non-Hodgkin lymphoma (15,16). Most of the mutations
are amino acid substitutions at or near the cofactor re-
cruitment sites deﬁned by our crystal structures
(15,19,20,38,39), suggesting that deregulated interactions
between MEF2 and its co-activators (CBP/p300) and/or
co-repressors (class IIa HDACs) may be involved in
tumorigenesis. Supporting this hypothesis are observa-
tions that CBP/p300 and class IIa HDACs are also fre-
quently mutated or deregulated in lymphoma/leukaemia
and other types of cancers (11,16,39). Remarkably,
BML-210 has been shown to induce growth inhibition,
apoptosis and differentiation in several leukeamia cell
lines (40). Whether BML-210 acts through MEF2 to
exert its anti-tumor effect will require further studies.
The structure and biochemical assays established here
helped us develop more speciﬁc and potent small
molecule inhibitors that can be used to address this
question and analyze the function of MEF2 and class
IIa HDACs. We have synthesized a series of new
compounds that inhibit the interaction between MEF2
and class IIa HDACs. Some of these compounds were
several folds more potent than BML-210 in inhibiting
the interaction. Therefore, our results and newly
introduced compounds provide leads for developing po-
tential epigenetic therapies against multiple diseases in
which deregulation of MEF2 and class IIa HDACs is
implicated.
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